Business Wire

FAIRBRICS

Share
Fairbrics Raises €22 M to Bring to Market its CO2-Based Polyester Fiber and Reduce the Textile Industry’s Carbon Footprint

Faibrics, a sustainable chemical company developing a technology that converts CO2 emissions into high value polyester through a circular manufacturing approach, announced today it has raised €17 M from the European Union’s Horizon 2020 Research & Innovation Program and 5 M€ from Partners to the Technology Upscaling Project, representing a total amount of €22 M to bring its innovative solution to market.

The EU’s grant was awarded to a consortium coordinated by Fairbrics that brings together 13 partners from 7 countries throughout Europe, ranging from upstream and process development experts (i.e. engineering design, CO2 capture, chemical reuse, electrolyzer) to final product specialists (i.e. Faurecia for automotive, Les Tissages de Charlieu for textile). To prompt societal impact, the Project also includes a strong educational component and, together with academic partners, it will develop learning and training resources on CO2 valorization for young professionals, university students and lifelong learners.

The combined funds will be used to upscale Fairbrics’ technology, first in a pilot line of 100 kg/day by 2024 and later, by 2026, in a 1 ton/day demo plant. The primary aim is to fight climate change and accelerate energy intensive industries’ decarbonation by replacing fossil-based polyester with CO2-based polyester, using a circular approach that recycles CO2 waste fumes from chemical plants into high value textile products. Fairbrics targets sectors employing polyester as a main material: clothing but also sports equipment, automotive and packaging.

“By using CO2 emissions instead of fossil resources to manufacture polyester, Fairbrics addresses one of the greatest global challenge, climate change caused greenhouse gas (GHG) emission. This funding comes as a strong recognition of the work Fairbrics has accomplished so far, the quality of the consortium we brought together, and the extraordinary potential of our technology to provide highly polluting industries like textile with an alternate environment-friendly and economically viable solution,” said Benoît Illy, Cofounder and CEO of Fairbrics.

Today, polyester accounts for 60% of all textiles produced worldwide and a third of the fashion industry’s GHG emission. By replacing fossil fuel sources by CO2-based sources, Fairbrics provides a sustainable and scalable solution to energy intensive industries. Fairbrics will initially address the fashion industry and has already secured strategic partnerships with major brands such as H&M, On-Running and Aigle. It intends to progressively diversify its technology platform with solutions addressing other sectors such as sports equipment, packaging and automotive.

About Fairbrics
Fairbrics is sustainable chemical company founded in 2019 and based in Paris (France). It has developed a disruptive patented technology platform that converts CO2 emissions into high value polyester fibers, providing energy intensive industries with environment-friendly and economically viable solutions. Fairbrics’ mission is to fight climate change by developing circular manufacturing process. Its technology has been demonstrated at lab-scale. Fairbrics has successfully secured partnerships with major fashion brands such as H&M, On-Running and Aigle. Next to clothing, the company intends to progressively deploy its technology to address other industries that employ polyester as their main material such as automotive and packaging. Fairbrics won several national and international innovation awards: Citeo Circular Challenge, French Tech Green20, I-Nov, Cleantech Open France, H&M Foundation’s Global Challenge Award. For more information: www.fairbrics.co

Partners to Fairbrics’ Technology Upscaling Project
Next to Fairbrics, participants to the Technology Upscaling Project include The University of Antwerp (Belgium), TECNALIA (Spain), Lappeenrannan Lahden teknillinen yliopisto (Finland), AIMPLAS (Spain), CiaoTech (Italy), Deutsche institute fur textil- und faserforschung denkendorf (Germany), CITY OF LAPPEENRANTA VILLMANSTRAND (Finland), DIGIOTOUCH OU (Estonia), Faurecia (France), Naldeo (France), SurePure (Belgium), Les Tissages de Charlieu (France).

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230116005284/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release

At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,

Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release

Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP

Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release

Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through

Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse

Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release

Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye